U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Cover of Innovation in Drug Research and Development for Prevalent Chronic Diseases

Innovation in Drug Research and Development for Prevalent Chronic Diseases

Proceedings of a Workshop

; Editors: Carolyn Shore, Rapporteur, Robert Pool, Rapporteur, Amanda Wagner Gee, Rapporteur, and Andrew March, Rapporteur.

Washington (DC): National Academies Press (US); .
ISBN-13: 978-0-309-09214-2ISBN-10: 0-309-09214-0

Investment and innovation in drug research and development (R&D) for highly prevalent chronic diseases has stalled in recent decades, despite half of all Americans living with at least one chronic disease. As a result, prevalent chronic diseases are producing immense health care costs as well as preventable suffering and death. On February 22, March 2, and March 8, 2021, the National Academies of Sciences, Engineering, and Medicine, convened a workshop to discuss barriers to innovation in this space and examine strategies and incentives to support equitable, person-centered drug R&D for prevalent chronic diseases.

Contents

This activity was supported by contracts between the National Academy of Sciences and Amgen Inc.; Association of American Medical Colleges; AstraZeneca; Biogen; Biomedical Advanced Research and Development Authority; Burroughs Wellcome Fund (Contract No. 1021334); Critical Path Institute; Eli Lilly and Company (Contract No. 4900709231); FasterCures, Milken Institute; Foundation for the National Institutes of Health; Friends of Cancer Research; Johnson & Johnson; Medable, Inc.; Merck & Co., Inc. (Contract No. MRLCPO-21-138769); National Institutes of Health (Contract No. HHSN263201800029I; Task Order No. HHSN26300007): National Cancer Institute, National Institute of Allergy and Infectious Diseases, National Institute of Mental Health, National Institute of Neurological Disorders and Stroke, Office of Science Policy; New England Journal of Medicine; Sanofi (Contract No. 65873711); Takeda Pharmaceuticals; U.S. Food and Drug Administration (Grant No. 1R13FD007302-01). Any opinions, findings, conclusions, or recommendations expressed in this publication do not necessarily reflect the views of any organization or agency that provided support for the project.

Suggested citation:

National Academies of Sciences, Engineering, and Medicine. 2021. Innovation in drug research and development for prevalent chronic diseases: Proceedings of a workshop. Washington, DC: The National Academies Press. https://doi.org/10.17226/26291.

Digital Object Identifier: https://doi.org/10.17226/26291

Additional copies of this publication are available from the National Academies Press, 500 Fifth Street, NW, Keck 360, Washington, DC 20001; (800) 624-6242 or (202) 334-3313; http://www.nap.edu.

Printed in the United States of America

Copyright 2021 by the National Academy of Sciences. All rights reserved.
Bookshelf ID: NBK574242PMID: 34591435DOI: 10.17226/26291

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (1.6M)

Related information

Similar articles in PubMed

See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...